Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 1;125(17):2915-2919.
doi: 10.1002/cncr.32184. Epub 2019 May 15.

Rapid research autopsy is a stealthy but growing contributor to cancer research

Eleonora Duregon  1 , Jowaly Schneider  1 , Angelo M DeMarzo  1 , Jody E Hooper  1
Affiliations

Rapid research autopsy is a stealthy but growing contributor to cancer research

Eleonora Duregon et al. Cancer. .

Abstract

Rapid autopsy has been shown to be a powerful tool for advancing research at essentially no risk and with no distress to the contributing patient. Academic and health centers with a substantial investment in cancer research should consider using this emerging research support modality.

Keywords: autopsy; cancer research; metastases; postmortem; rapid autopsy; tumor heterogeneity.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures of potential conflicts of interest: Nothing to disclose.

Figures

Figure 1:
Figure 1:
Research methodologies that can be supported by rapid research autopsy tissue resources
See this image and copyright information in PMC

References

    1. Khalil DN, Smith EL, Brentjens RJ, et al.: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13:394, 2016. - PMC - PubMed
    1. Sharpe AH, Pauken KE: The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol, 2017. - PubMed
    1. Dzobo K, Senthebane DA, Thomford NE, et al.: Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development. OMICS 22:17–34, 2018. - PubMed
    1. Steeg PS: Targeting metastasis. Nat Rev Cancer 16:201–18, 2016. - PMC - PubMed
    1. Ma W, Gilligan BM, Yuan J, et al.: Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 9:47, 2016. - PMC - PubMed

Publication types